Hurvitz, N.; Dinur, T.; Revel-Vilk, S.; Agus, S.; Berg, M.; Zimran, A.; Ilan, Y.
A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy. J. Clin. Med. 2024, 13, 3325.
https://doi.org/10.3390/jcm13113325
AMA Style
Hurvitz N, Dinur T, Revel-Vilk S, Agus S, Berg M, Zimran A, Ilan Y.
A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy. Journal of Clinical Medicine. 2024; 13(11):3325.
https://doi.org/10.3390/jcm13113325
Chicago/Turabian Style
Hurvitz, Noa, Tama Dinur, Shoshana Revel-Vilk, Samuel Agus, Marc Berg, Ari Zimran, and Yaron Ilan.
2024. "A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy" Journal of Clinical Medicine 13, no. 11: 3325.
https://doi.org/10.3390/jcm13113325
APA Style
Hurvitz, N., Dinur, T., Revel-Vilk, S., Agus, S., Berg, M., Zimran, A., & Ilan, Y.
(2024). A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy. Journal of Clinical Medicine, 13(11), 3325.
https://doi.org/10.3390/jcm13113325
